Health Care • Biotechnology: Pharmaceutical Preparations
$29.99 ▼ -0.88
(-2.85%)
MKT CAP: $2.24B • VOL: 1.36M
52W L $11 52W H $34
SDGR // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $255.9M | $207.5M | $216.7M |
| YoY Revenue Growth % | +23.3% | -4.2% | — |
| Gross Profit | $142.6M | $132.1M | — |
| Gross Margin % | 55.7% | 63.6% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$166.9M | -$209.3M | -$177.4M |
| Operating Margin % | -65.2% | -80.0% | -80.0% |
| Net Income (GAAP) | -$103.3M | -$187.1M | $40.7M |
| EBITDA (Normalized) | -$165.7M | -$203.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $13.9M | -$157.4M | -$136.7M |
| Capital Expenditures (CapEx) | $1.4M | $7.3M | — |
| Free Cash Flow (FCF) | $12.5M | -$164.7M | -$136.7M |
| FCF Margin % | 4.9% | -79.3% | -63.1% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $230.5M | $147.3M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $364.1M | $421.4M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR SDGR.